Company profile
Definium Therapeutics, Inc.
NASDAQ:DFTXMedicinal Chemicals and Botanical Products
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LYSERGIDE D-TARTRATE | phase3 | — | 6 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05407064 | phase2 | completed | 2022-08-24 | 2023-10-06 | Definium Therapeutics US, Inc. | A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms |
| NCT07303907 | phase2 | recruiting | 2025-12-03 | 2027-08-01 | Definium Therapeutics US, Inc. | A Phase 2A Trial of DT402 for Autism Spectrum Disorder |
| NCT06741228 | phase3 | active_not_recruiting | 2024-12-11 | 2026-07-15 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) |
| NCT07592689 | phase3 | recruiting | 2026-05-10 | 2027-09-01 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
| NCT06941844 | phase3 | active_not_recruiting | 2025-04-14 | 2026-05-20 | Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) |
FDA applications (0)
No records yet.